Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Juan Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8190-3524; OpenAlex author ID A5045364810. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2021: 1 paper · 2022: 5 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 11

  1. Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgica… Co-author DOI 10.1080/07853890.2025.2541314↗
  2. Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical t… Last author DOI 10.1007/s00262-024-03744-z↗
  3. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: … Last author DOI 10.1038/s41392-024-01857-6↗
  4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Last author DOI 10.3389/fimmu.2024.1210859↗
  5. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Last author DOI 10.1080/21645515.2023.2178791↗
  6. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Last author DOI 10.1080/21645515.2022.2143154↗
  7. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Co-author DOI 10.3389/fimmu.2022.799026↗
  8. Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancre… Co-author DOI 10.3389/fonc.2022.1015232↗
  9. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic… Last author DOI 10.3389/fonc.2022.782730↗
  10. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Co-author DOI 10.3389/fonc.2022.844527↗
  11. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Last author DOI 10.3389/fonc.2021.693386↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baorui Liu · 9 shared papers, 2021–2024 · strength 1.42
  2. Changchang Lu · 7 shared papers, 2021–2024 · strength 1.09
  3. Xin Qiu · 7 shared papers, 2021–2024 · strength 1.09
  4. Fan Tong · 5 shared papers, 2022–2024 · strength 0.90
  5. Huizi Sha · 5 shared papers, 2021–2025 · strength 0.88
  6. Qiao-Li Wang · 3 shared papers, 2022–2024 · strength 0.52
  7. Yudong Qiu · 3 shared papers, 2022–2025 · strength 0.48
  8. Juan Liu · 2 shared papers, 2022–2024 · strength 0.37
  9. Zhan Shi · 2 shared papers, 2022–2023 · strength 0.34
  10. Song Zhang · 1 shared paper, 2025 · strength 0.21
  11. Jun Chen · 1 shared paper, 2025 · strength 0.21
  12. Elyar Abaydulla · 1 shared paper, 2025 · strength 0.21
  13. Shanshan Shen · 1 shared paper, 2025 · strength 0.21
  14. Hao Cheng · 1 shared paper, 2025 · strength 0.21
  15. Liang Qi · 1 shared paper, 2024 · strength 0.20
  16. Qin Wang · 1 shared paper, 2024 · strength 0.20
  17. Jie Shao · 1 shared paper, 2022 · strength 0.14
  18. Xiaoling Gong · 1 shared paper, 2022 · strength 0.14
  19. Yujie Zhou · 1 shared paper, 2022 · strength 0.14
  20. Wangshu Dai · 1 shared paper, 2021 · strength 0.14
  21. Lei Wang · 1 shared paper, 2022 · strength 0.13
  22. Jian He · 1 shared paper, 2022 · strength 0.13
  23. Qi Li · 1 shared paper, 2022 · strength 0.13
  24. Xin Zhang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.